Month: August 2021
Excerpt from the Press Release: PEABODY, Mass., Aug. 19, 2021 /PRNewswire/ — Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal cancers, announced today that Privo and its CEO, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition. Privo was selected from…
Read MoreExcerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of…
Read MoreExcerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Aug. 19, 2021– Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s cerebrospinal fluid assay, CNSide™, detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, allowing for targeted treatment decisions that may improve outcomes…
Read MoreExcerpt from the Press Release: GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced the addition of Yehia Hashad, MD to its Board of Directors.…
Read MoreExcerpt from the Press Release: Pluto Biosciences, a biotech software startup, launched its cloud-based, collaborative life sciences platform that leverages technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The Pluto platform simplifies secure, collaborative data sharing and bioinformatics analysis for academic, biotech, and pharmaceutical organizations. The Pluto platform was built to…
Read MoreSoligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
Excerpt from the Press Release: PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines…
Read MoreExcerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development.…
Read MoreExcerpt from the Press Release: SUNNYVALE, Calif. & PITTSBURGH, Pa.–(BUSINESS WIRE)–Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras…
Read MoreExcerpt from the Press Release: Gritstone bio is developing Covid-19 vaccines that use self-amplifying messenger RNA, which is intended to further boost the immune response compared to mRNA alone. The company also says its vaccine candidates may be able to protect against variants of the novel coronavirus. As coronavirus variants continue to fuel the ongoing…
Read MoreExcerpt from the Press Release: The FDA wanted a couple more clinical studies for Qualigen’s investigational COVID-19 antiviral before human testing, but the biotech is calling it quits instead. Shares of the company plunged nearly 20% to $1.34 as the markets opened Tuesday, underscoring the risk that small companies take on when trying to jump…
Read More